2595 Phase II study of pazopanib as second-line treatment aftersunitinib in patients with metastatic renal cell carcinoma: A Southern China Urology Cancer Consortium Trial. (September 2015) - Xie, M.; He, C.; Huang, J.; Lin, Q.